is semaglutide a compound drug FDA Warns on Certain Forms of Compounded Semaglutide for weight loss |

The eyecare practitioner should communicate the small possible risk of NAION, while acknowledging that a causal association with GLP-1 drugs has not been established, to other members of the care team to better inform prescribing decisions

doi: 10.2337/dc12-2454 51 WildingJPHBatterhamRLCalannaSDaviesMVan GaalLFLingvayIet al

An alternative are anti-diabetic agents such as the GLP-1 mimetics which have been developed to normalise insulin signalling in diabetic patients with great success

Discontinuation and Duration Dependent Cardiovascular Risk Compared with continual use of GLP-1s, discontinuing treatment for 6 months was associated with a 4% increased risk of major adverse cardiovascular events

The GIP and glucagon receptor effects take longer to manifest at measurable levels

Another trial on 1,210 people found similarly promising results, with those taking 2.4 mg of semaglutide reducing their body weight by 9.6% compared to 3.4% in the placebo group over 68 weeks of treatment